MILESTONE SCIENTIFIC INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) | MarketScreener

2022-05-20 23:56:10 By : Ms. Frieda Ann

Milestone Scientific remains focused on advancing efforts to achieve the following three primary objectives:

? Establishing Milestone's DPS Dynamic Pressure Sensing technology platform as

the standard-of-care in painless and precise drug delivery, providing for the

first time, objective visual and audible in-tissue pressure feedback, and

continuing to expand platform applications;

? Following obtaining successful FDA clearance of our first medical device,

Milestone Scientific is transitioning from a research and development

organization to a commercially focused medical device company; and

? Expanding our global footprint of our CompuFlo Epidural and CathCheck System by

utilizing a direct field sales force and partnering with distribution companies

Since its market introduction in early 2007, the Wand STA System and prior C-CLAD devices have been used to deliver over 80 million safe, effective, and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the STA Instrument is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide.

The following table shows a breakdown of Milestone Scientific's product sales (net), domestically and internationally, by business segment product category:

Domestic: US Dental Medical Grand Total Dental Medical Grand Total Instruments

See Note 1, "Organization and Business".

Three months ended March 31, 2022 compared three months ended March 31, 2021

Net sales for 2022 and 2021 were as follows:

Gross Profit for 2022 and 2021 were as follows:

Consolidated gross profit for each of the three months ended March 31, 2022 and 2021 was approximately 62%.

Selling, general and administrative expenses 2022 and 2021 were as follows:

Research and Development for 2022 and 2021 were as follows:

Profit (Loss) from Operations for 2022 and 2021 were as follows:

© Edgar Online, source Glimpses